Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07789223

Weight and Metabolic Management Study

Weight and Metabolic Management Study — Recruiting • Non-phase study • Diabetes / Metabolic • NCT07789223.

📅 17 Sep 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07789223
Start
2026-09-15
Completion
2027-02
ClinicaliQ Trial Snapshot
  • Weight and Metabolic Management Study — Recruiting • Non-phase study • Diabetes / Metabolic • NCT07789223.
  • A 16-week study testing whether a nutritional supplement helps adults lose weight or prevent regain after stopping GLP-1 medications.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them. The main question it aims to answer is: Does taking elénzia CONTROL® for 16 weeks help reduce body weight in adults who have never used GLP-1 medications or help prevent weight regain in adults who have recently stopped using them? The study will also look at changes in appetite, sugar cravings, mood, energy, diet, sleep,…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management
Diabetes / Metabolic · 06 Jul 2016
Assess all patients with MASLD using FIB-4 index or transient elastography to stratify fibrosis risk—those with advanced fibrosis require specialist hepatology referral…
View guideline →
Clinical Brief
Daily pill to help keep weight off after stopping obesity jabs
Diabetes / Metabolic · BBC Health · 12 May 2026
Orforglipron is a daily oral tablet offering an alternative to GLP-1 receptor agonist injections for weight maintenance after obesity treatment cessation The…
View brief →
Guideline
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Diabetes / Metabolic · 27 Mar 2026
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services…
View guideline →
Guideline
Obesity: Identification, Assessment and Management (NICE CG189)
Diabetes / Metabolic · 27 Mar 2026
Use BMI thresholds to identify obesity (≥30 kg/m² in adults; ≥27.5 kg/m² in Asian populations) and offer structured first-line weight loss interventions…
View guideline →
Podcast
GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
Diabetes / Metabolic · 00:15:32 · 03 Apr 2026
GLP-1 receptor agonists mimic gut-derived GLP-1: they increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying. Semaglutide is a once-weekly GLP-1…
Listen →
Guideline
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Diabetes / Metabolic · 27 Mar 2026
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m²…
View guideline →